ADVERTISEMENT

Coronavirus vaccine developer Moderna soared 30% as US stocks suffered their worst stretch in years. Here are the 10 investors that benefited most — and how much they made. (MRNA)

Investors are posting multimillion-dollar gains from Moderna's soaring stock price, profiting from the company's bid to offer a coronavirus vaccine.

Moderna biotech lab laboratory pharma
  • Moderna spiked 30% between Monday and Tuesday's trading sessions. The biotech firm was one of the few US stocks to post major gains while the broader market slumped on intensifying outbreak concerns.
  • Here are the top 10 Moderna shareholders and how much they profited from the two-day rally, ranked in ascending order.
  • Watch Moderna trade live here .
ADVERTISEMENT

Investors are pulling in hundreds of millions of dollars worth of gains from soaring biotech stocks as the race for coronavirus drugs intensifies.

Drug developer Moderna spiked 30% between Monday and Tuesday's trading sessions, beating out a plunging market by shipping the first coronavirus vaccine for human testing. The firm submitted vials of mRNA-1273 for phase one trials in the US just 42 days after identifying the key RNA sequence to target, according to a Monday press release.

Moderna shares gained 2% on Monday as the broader market slumped the most in two years. The biotech company soared as much as 43% in Tuesday's session before paring some gains.

ADVERTISEMENT

Moderna's stock jump arrived one day after biotech company Gilead notched a similar uptick. The firm soared as much as 11% Monday after a World Health Organization official said its remdesivir compound could be the best bet for treating coronavirus cases. Gilead's drug is undergoing human trials in China, with results expected to be released in April.

Here are the top 10 shareholders to ride Moderna's two-day stock rally, ranked in ascending order of profit. Gain figures are calculated from the spike between February 21's close and the closing price on February 25. Holdings data are sourced from Bloomberg.

Steven Ferdman/Getty Images

ADVERTISEMENT

Shares held: 7,456,986

Gain: $41,237,133

About: Bancel serves as the biotech company's CEO and as a venture partner for Flagship Pioneering, the firm that founded Moderna. He previously acted as CEO at French diagnostics company bioMrieux and at Eli Lilly and Company.

ADVERTISEMENT

Reuters

Shares held: 7,953,216

Gain: $43,981,284

About: Bancel serves as the majority equity holder and sole managing member of OCHA. The CEO has previously used the LLC to buy Moderna stock.

ADVERTISEMENT

picture alliance/Getty Images

Shares held: 9,232,886

Gain: $51,057,860

About: Boston Biotech Ventures serves as another holding firm for Bancel to buy and sell Moderna shares.

ADVERTISEMENT

Moderna

Shares held: 10,828,850

Gain: $59,883,541

ADVERTISEMENT

About: TAS serves as a holding company for Dr. Timothy Springer and Dr. Chafen Lu. Springer has helped several young biotech companies get off the ground, and was among Moderna's biggest shareholders before its initial public offering.

Tim Mosenfelder/Getty Images

Shares held: 11,509,357

ADVERTISEMENT

Gain: $63,646,744

About: A scientist, inventor, chemical engineer, and professor at MIT, Langer serves on Moderna's board of directors. He has helped found several other biotech firms, both on his own and in partnership with venture capital firm Polaris Partners.

Reuters

ADVERTISEMENT

Shares held: 11,724,018

Gain: $64,833,820

About: BlackRock holds Moderna shares across several investment products. Moderna is the highest-weighted company in BlackRock's iShares Genomics Immunology and Healthcare ETF.

ADVERTISEMENT

Moderna

Shares held: 16,034,456

Gain: $88,670,542

About: Fidelity holds millions of shares of Moderna through the numerous index funds it offers to clients.

ADVERTISEMENT

REUTERS/Tim Shaffer

Shares held: 17,319,037

Gain: $95,774,275

About: Investment adviser giant Vanguard holds millions of Moderna shares through several of its funds, including its Total Stock Market Index Fund, Small-Cap ETF, and Extended Market ETF.

ADVERTISEMENT

Reuters

Shares held: 25,499,325

Gain: $141,011,267

ADVERTISEMENT

About: AstraZeneca and Moderna announced an exclusive partnership to develop messenger RNA therapeutics in 2013 for numerous serious diseases and cancers. AstraZeneca made an upfront investment of $240 million for exclusive access to targeting specific diseases through the therapeutics.

Moderna

Shares held: 50,867,600

ADVERTISEMENT

Gain: $281,297,828

About: A well-known healthcare venture capital fund, Flagship Pioneering founded Moderna in 2010. The biotech company's CEO joined Flagship in 2013 and serves as a venture partner.

Now read more markets coverage from Markets Insider and Business Insider:

'The brink of a global recession': A financial expert warns of severe coronavirus fallout as markets tank

SmileDirectClub plummets 24% after missing quarterly estimates and reining in expansion plans

ADVERTISEMENT

Wall Street thinks Disney's new CEO Bob Chapek will be the company's profit protector as it undergoes a radical transformation

See Also:

FOLLOW BUSINESS INSIDER AFRICA

Unblock notifications in browser settings.
ADVERTISEMENT

Recommended articles

Sony’s creators convention redefines the creative landscape for content creators

Sony’s creators convention redefines the creative landscape for content creators

Egypt, Nigeria, and South Africa ranked as Africa's most polluted countries in new report

Egypt, Nigeria, and South Africa ranked as Africa's most polluted countries in new report

10 African countries with the lowest life expectancy according to the World Bank

10 African countries with the lowest life expectancy according to the World Bank

Kenyan women are more obese than their men - here’s why

Kenyan women are more obese than their men - here’s why

Africa’s richest man Dangote stands between Europe and $17 billion in revenue

Africa’s richest man Dangote stands between Europe and $17 billion in revenue

After months of exchanging blows, Kenya and Uganda takes steps towards resolution

After months of exchanging blows, Kenya and Uganda takes steps towards resolution

Africa's first black billionaire could join $2.9 billion Vivendi bid for MultiChoice

Africa's first black billionaire could join $2.9 billion Vivendi bid for MultiChoice

10 most dangerous African countries in 2024

10 most dangerous African countries in 2024

Russia’s nuclear influence expands further north of Africa

Russia’s nuclear influence expands further north of Africa

ADVERTISEMENT